Trading Report: The John P. Engels invests in 4,000 by purchasing AxoGen Inc. (AXGN) Stock shares

The John P. Engels invests in 4,000 by purchasing AxoGen Inc. (AXGN) Stock shares

AxoGen Inc. (NASDAQ:AXGN) VP John P. Engels acquired 4,000 shares of AxoGen stock in a transaction on Friday, October 7th. The shares were bought at an average cost of $7.50 per share, for a total transaction of $30,000.00. Following the completion of the transaction, the vice president now owns 98,425 shares in the company, valued at approximately $738,187.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

AxoGen Inc. (NASDAQ:AXGN) opened at 8.70 on Tuesday. AxoGen Inc. has a 12 month low of $4.08 and a 12 month high of $9.88. The stock’s market capitalization is $262.15 million. The firm’s 50-day moving average is $8.74 and its 200-day moving average is $7.04.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, August 3rd. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.03. AxoGen had a negative net margin of 37.90% and a negative return on equity of 193.60%. On average, equities analysts expect that AxoGen Inc. will post ($0.40) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of AXGN. Schwab Charles Investment Management Inc. acquired a new position in AxoGen during the second quarter worth $264,000. G2 Investment Partners Management LLC acquired a new position in AxoGen during the second quarter worth $347,000. Bridgeway Capital Management Inc. acquired a new position in AxoGen during the second quarter worth $1,241,000. Menta Capital LLC acquired a new position in AxoGen during the second quarter worth $183,000. Finally, KCG Holdings Inc. acquired a new position in AxoGen during the second quarter worth $200,000. 57.87% of the stock is owned by hedge funds and other institutional investors.

Separately, Wedbush reissued an “outperform” rating and set a $10.00 price objective (up from $9.00) on shares of AxoGen in a research report on Thursday, August 4th.

Related posts

Leave a Comment